Hepatic allograft rejection under quadruple immunosuppressive regimen with cyclosporine A in liver transplantation: incidence of viral and fungal infection.
Fabregat
J
J
Liver Transplant Unit, Universidad de Barcelona, Spain.
Fradera
R
R
Figueras
J
J
Rafecas
A
A
Torras
J
J
Martinez LaCasa
J
J
Baliellas
C
C
Casais
L
L
Jaurrieta
E
E
D000293:Adolescent; D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000453:epidemiology*; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D015994:Incidence; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009181:Mycoses / Q000453:epidemiology* / Q000517:prevention & control; D009761:Nystatin / Q000627:therapeutic use; D011446:Prospective Studies; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D009761:Nystatin; D016572:Cyclosporine; D008775:Methylprednisolone